Moonlake Immunotherapeutics Quick Ratio (MLTX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Moonlake Immunotherapeutics  (NASDAQ: MLTX)

Moonlake Immunotherapeutics's Quick Ratio

MLTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 6.5 below Moonlake Immunotherapeutics average.

Within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Quick Ratio than Moonlake Immunotherapeutics in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 0 to 336.

Explain Quick Ratio?
How much Cash & cash equivalents MLTX´s has?
What are MLTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MLTX/financial-strength
https://api.csimarket.com/api/v1/companies/MLTX/fundamentals
https://api.csimarket.com/api/v1/companies/MLTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MLTX Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 20.8 %
Y / Y Cash & cash equivalent Change -0.2 %
Quick Ratio MRQ 6.5
MLTX's Total Ranking # 336
Seq. Current Liabilities Change 28.72 %
Seq. Cash & cash equivalent Change -29.29 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 91
Healthcare Sector # 132
Overall Market # 336


Quick Ratio Statistics
High Average Low
70.33 21.64 0
(Jun 30 2023)   (Mar 31 2022)




Financial Statements
Moonlake Immunotherapeutics's Current Liabilities $ 58 Millions Visit MLTX's Balance sheet
Moonlake Immunotherapeutics's Cash & cash equivalent $ 380 Millions Visit MLTX's Balance sheet
Source of MLTX's Sales Visit MLTX's Sales by Geography


Cumulative Moonlake Immunotherapeutics's Quick Ratio

MLTX's Quick Ratio for the trailling 12 Months

MLTX Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 59.95 %
Y / Y Cash & cash equivalent TTM Growth -3.76 %
Quick Ratio TTM 8.54
Total Ranking TTM # 3392
Seq. Current Liabilities TTM Growth 5.43 %
Seq. Cash & cash equivalent TTM Growth -0.05 %

Quick ratio ranking by company, industry and sector >> Back to MLTX Financial Strength Comparisons >> Go to Compare MLTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $58.43 millions, cumulative Quick Ratio decreased to 8.54 below the Moonlake Immunotherapeutics average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Moonlake Immunotherapeutics. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 0 to 3392.

Explain Quick Ratio?
How much Cash & cash equivalents MLTX´s has?
What are MLTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 415
Healthcare Sector # 844
Within the Market # 3392


trailing twelve months Quick Ratio Statistics
High Average Low
56.61 19.98 0.01
(Mar 31 2024)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Arrivent Biopharma inc   16.86 $ 393.691  Millions$ 23.357  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Immunome Inc   11.27 $ 461.582  Millions$ 40.966  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions
Xenon Pharmaceuticals Inc   10.99 $ 950.798  Millions$ 86.487  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Abcellera Biologics Inc   10.85 $ 764.424  Millions$ 70.473  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions
Bicycle Therapeutics Plc  10.57 $ 469.928  Millions$ 44.459  Millions
Lipocine Inc   10.55 $ 21.455  Millions$ 2.034  Millions
Cyclerion Therapeutics Inc   10.32 $ 456.221  Millions$ 44.197  Millions
Lexicon Pharmaceuticals Inc   10.31 $ 183.203  Millions$ 17.773  Millions

Date modified: 2026-11-05T05:30:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.